CEO Brian Lian stated, "We are advancing this compound into Phase 3 development," while highlighting the preparation for an end-of-phase 2 meeting with the agency expected later this year.
Positive results reported in Phase 1 trials include a mean weight loss of up to 5.3% from baseline after 28 days, showcasing substantial safety and tolerability.
Analysts at Truist reiterated a buy rating on VKTX stock with a $105 price target, arguing that demand for obesity treatments remains robust.
The obesity drug treatment market could be worth $150 billion by 2033, as highlighted by analysts at BMO Capital Markets, indicating substantial long-term growth potential.
Collection
[
|
...
]